Management of Allergic Rhinitis

ARIA Classification

Management Algorithm (ARIA)

1. Allergen Avoidance

• Identify triggers via skin prick testing or serum allergen-specific IgE (ImmunoCAP)
• Common seasonal triggers: tree and grass pollens
• Common perennial triggers: house dust mites, pet dander, mold
• Environmental measures (mattress covers, HEPA filters, pet removal) reduce allergen load
• Saline nasal irrigation provides modest symptomatic benefit and may reduce medication need

2. Pharmacotherapy

A. Intranasal Corticosteroids (INCs) - First-line for moderate-severe / persistent AR

• Most effective monotherapy for all four cardinal symptoms, especially nasal congestion
• Require consistent daily use - no effect when used as-needed; maximal benefit over days to weeks
• Administration technique: clear nasal mucus first, tilt head slightly forward, direct spray laterally (away from septum) to reduce epistaxis risk
• Adverse effects: Local irritation, sneezing, epistaxis. At high cumulative doses (especially with concurrent inhaled steroids): reduced growth velocity in children, adrenal suppression - growth monitoring recommended
• A 2025 network meta-analysis (PMID: 39548801) confirmed INCs have superior efficacy compared to oral treatments for nasal symptoms

B. Oral H1-Antihistamines - First-line for mild/episodic AR

• Target rhinorrhea, sneezing, and itching - do NOT relieve nasal congestion
• 2nd-generation agents: once-daily dosing (12-24 h duration), minimal CNS penetration, no significant sedation
• 1st-generation agents: avoid in patients requiring alertness; anticholinergic side effects (dry mouth, urinary retention, blurred vision)
• Metabolized by hepatic CYP450 (except cetirizine/levocetirizine - excreted unchanged in urine; fexofenadine - in feces)

C. Intranasal Antihistamines

• Faster onset of action than INCs - useful for acute breakthrough symptoms
• Adverse effects: Bitter taste, systemic absorption with potential for sedation

D. Intranasal Combination (INC + Intranasal Antihistamine)

• For moderate-severe AR: superior rapidity and magnitude of relief compared to either agent alone
• A 2024 systematic review (PMID: 38685482) found combined intranasal antihistamines + corticosteroids have additive benefit over monotherapy

E. Decongestants

• Relieve nasal congestion rapidly
• Intranasal decongestants: Limit to <3-5 days to avoid rhinitis medicamentosa (rebound congestion)
• Oral decongestants: Avoid in hypertension, cardiovascular disease, hyperthyroidism, glaucoma, BPH

F. Leukotriene Receptor Antagonists (LTRAs)

• Consider when other therapies are ineffective or not tolerated; more effective in combination with antihistamines
• Important: FDA black box warning for serious neuropsychiatric events (depression, suicidal ideation) - reserve for patients where benefits outweigh risks

G. Ipratropium Nasal Spray

• Add-on for predominant rhinorrhea when INCs alone are insufficient
• Also useful in vasomotor (non-allergic) rhinitis

H. Cromones (Cromolyn Sodium)

• Mast cell stabilizer; safe profile but less efficacious than INCs
• Requires frequent dosing (3-4x/day)
• Useful in pregnancy or where steroid exposure is to be minimized

I. Ocular Symptoms (Allergic Conjunctivitis)

• Topical H1-antihistamines (ketotifen, olopatadine, azelastine) or mast cell stabilizers (cromolyn, lodoxamide)
• Oral antihistamines also help
• Avoid topical steroids unless directed by an ophthalmologist

3. Immunotherapy - Disease-Modifying Treatment

Subcutaneous Immunotherapy (SCIT)

• Weekly subcutaneous injections with gradually escalating antigen doses; total course 2-3 years
• Most well-studied approach in the US
• Risk: Rare anaphylaxis (must be administered in a clinical setting with emergency equipment)

Sublingual Immunotherapy (SLIT)

• FDA-approved products for timothy grass (Grastek), five grass pollens (Oralair), dust mites (Odactra), and short ragweed (Ragwitek)
• Can be self-administered at home; avoids injections
• Higher rate of mild local mucosal side effects; systemic reactions rarer than SCIT
• SCIT and SLIT have similar overall efficacy; head-to-head trials are limited

Indications for Immunotherapy

• Symptoms inadequately controlled with pharmacotherapy and avoidance
• Patient desiring disease modification rather than just symptom suppression
• Not recommended: Poorly controlled asthma, poor medication adherence
• Not well-studied in children under 5 years
• May reduce risk of new-onset asthma in AR patients

4. Step-Up/Step-Down Strategy

5. Special Considerations

• AR and asthma: 80% of patients with allergic asthma also have AR. Screen persistent/moderate-severe AR patients for asthma. INCs benefit both conditions (unified airway)
• Pregnancy: Prefer intranasal cromolyn or loratadine (category B); avoid decongestants especially in first trimester
• Children: Prefer 2nd-generation oral antihistamines or intranasal steroids; monitor growth with long-term INC use; immunotherapy not well-studied under age 5
• Montelukast: Use with caution given neuropsychiatric warning; not preferred first-line

Recent Evidence (2024-2025)

• [PMID 38685482] (J Allergy Clin Immunol 2024): Intranasal antihistamines + corticosteroids are superior to either alone - supporting combined intranasal therapy for moderate-severe AR
• [PMID 39251016] (J Allergy Clin Immunol Pract 2024): Intranasal treatments outperform oral treatments for nasal symptom control
• [PMID 39548801] (Allergy 2025): Network meta-analysis confirms INC monotherapy as most efficacious intranasal option; combination INC+antihistamine provides additional benefit